Managers / Q3 2023 · view latest →
Versant Venture Management, LLC
CIK 0001560009 · ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO, CA, 94104 · 650-233-7877
Summary
Versant Venture Management, LLC reported $188M in U.S.-listed holdings across 8 positions for Q3 2023.
The portfolio is heavily concentrated: Rayzebio alone accounts for 60.9% of reported value.
Compared with Q2 2023, the fund opened 1 new position and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 63.7% · $120M
- Common Stock · 36.3% · $68M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| RayzeBio, Inc. | NEW | +5.16M | 5.16M | +$115M | $115M |
| CymaBay Therapeutics, Inc. | SOLD OUT | −543.8K | 0 | −$6M | $0 |
| Minerva Surgical Inc. | TRIMMED | −1.59M | 83.7K | −$153,482 | $275,320 |
| CRSPCRISPR Therapeutics AG | HELD | +0 | 498.6K | −$5M | $23M |
| RPTXRepare Therapeutics, Inc. | HELD | +0 | 2.65M | +$4M | $32M |
| Passage Bio, Inc. | HELD | +0 | 4.96M | −$1M | $3M |
| Gritstone Oncology, Inc. | HELD | +0 | 3.56M | −$819,065 | $6M |
| Aligos Therapeutics, Inc. | HELD | +0 | 2.32M | −$519,765 | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | RayzeBio, Inc. | Common Stock | 60.87% | $115M | 5.16M |
| 2 | RPTXRepare Therapeutics, Inc.history → | Common Stock | 17.00% | $32M | 2.65M |
| 3 | CRSPCRISPR Therapeutics AGhistory → | Common Shares | 12.03% | $23M | 498.6K |
| 4 | Adverum Biotechnologies, Inc. | Common Stock | 4.04% | $8M | 5.07M |
| 5 | Gritstone Oncology, Inc. | Common Stock | 3.26% | $6M | 3.56M |
| 6 | Passage Bio, Inc. | Common Stock | 1.73% | $3M | 4.96M |
| 7 | Aligos Therapeutics, Inc. | Common Stock | 0.92% | $2M | 2.32M |
| 8 | Minerva Surgical Inc. | Common Stock | 0.15% | $275,320 | 83.7K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $141M | 8 | May 5, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $151M | 7 | Feb 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $212M | 9 | Nov 10, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $82M | 8 | Aug 11, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $60M | 7 | May 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $87M | 7 | Feb 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $64M | 6 | Nov 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $77M | 8 | Aug 7, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $103M | 7 | May 3, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $389M | 7 | Feb 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $188M | 8 | Nov 3, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $84M | 8 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $48M | 7 | May 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $48M | 7 | Feb 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $59M | 8 | Nov 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $65M | 8 | Aug 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $100M | 10 | May 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $187M | 10 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $242M | 11 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $302M | 11 | Aug 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $513M | 11 | May 7, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $963M | 12 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | Under review | 11 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $696.1B | 12 | Jul 20, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $364.6B | 9 | Apr 28, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $331.8B | 7 | Jan 21, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $258.5B | 8 | Oct 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $343.2B | 9 | Jul 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $303.6B | 9 | Apr 5, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $202.0B | 10 | Jan 22, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.